News
22h
GlobalData on MSNVertex and NHS England agree reimbursement for AlyftrekVertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...
Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...
Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...
Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.
It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...
US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...
Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...
NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results